Zobrazeno 1 - 10
of 417
pro vyhledávání: '"Mark D. Okusa"'
Autor:
Tsuyoshi Inoue, Yasuna Nakamura, Shinji Tanaka, Takahide Kohro, Lisa X. Li, Liping Huang, Junlan Yao, Suzuka Kawamura, Reiko Inoue, Hiroshi Nishi, Daichi Fukaya, Rie Uni, Sho Hasegawa, Reiko Inagi, Ryusuke Umene, Chia-Hsien Wu, Hong Ye, Amandeep Bajwa, Diane L. Rosin, Katsuhiko Ishihara, Masaomi Nangaku, Youichiro Wada, Mark D. Okusa
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Chronic kidney disease is a progressive disease that may lead to end-stage renal disease. Interstitial fibrosis develops as the disease progresses. Therapies that focus on fibrosis to delay or reverse progressive renal failure are limited. We and oth
Externí odkaz:
https://doaj.org/article/03753dcdcc41406baecd35c7190471d3
Autor:
Diane L. Rosin, J. Perry Hall, Shuqiu Zheng, Liping Huang, Silvia Campos-Bilderback, Ruben Sandoval, Andrea Bree, Kevin Beaumont, Emily Miller, Jennifer Larsen, Ghazal Hariri, Neelu Kaila, Iain M. Encarnacion, Jeremy D. Gale, Andrea van Elsas, Bruce A. Molitoris, Mark D. Okusa
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Adenosine triphosphate (ATP) released from injured or dying cells is a potent pro-inflammatory “danger” signal. Alkaline phosphatase (AP), an endogenous enzyme that de-phosphorylates extracellular ATP, likely plays an anti-inflammatory role in im
Externí odkaz:
https://doaj.org/article/8a48422a8c3f4fea9d0b25430207d3fe
Autor:
William T. Nash, Mark D. Okusa
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Immune dysregulation in acute kidney injury (AKI) is an area of intense interest which promises to enhance our understanding of the disease and how to manage it. Macrophages are a heterogeneous and dynamic population of immune cells that carry out mu
Externí odkaz:
https://doaj.org/article/76ebf58b779c4c529f1fe40fd45f1f10
Publikováno v:
Bioelectronic Medicine, Vol 5, Iss 1, Pp 1-11 (2019)
Abstract Neuroimmunomodulation through peripheral nerve activation is an important therapeutic approach to various disorders. Central to this approach is the inflammatory reflex pathway in which the cholinergic anti-inflammatory pathway represents th
Externí odkaz:
https://doaj.org/article/3466f69988e64462a1029446a8d8a850
Autor:
Mark D. DeBoer, Stephanie L. Filipp, Solomon K. Musani, Mario Sims, Mark D. Okusa, Matthew Gurka
Publikováno v:
Kidney & Blood Pressure Research, Vol 43, Iss 2, Pp 555-567 (2018)
Background/Aims: The metabolic syndrome (MetS), as assessed using dichotomous criteria, is associated with increased risk of future chronic kidney disease (CKD), though this relationship is unclear among African Americans, who have lower risk for Met
Externí odkaz:
https://doaj.org/article/a1320deba1624b50bfe4a8933d4bed0d
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Inflammation contributes to the pathogenesis of a wide variety of disorders including kidney diseases. Recent advances have shown that neural pathways are able to regulate immunity and inflammation. The cholinergic anti-inflammatory pathway (CAP) is
Externí odkaz:
https://doaj.org/article/9425f577600e442287f19709dcfdd7d3
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Natural IgM anti-leukocyte autoantibodies (IgM-ALAs) inhibit inflammation by several mechanisms. Here, we show that pan-B cells and bone marrow-derived dendritic cells (BMDCs) are switched to regulatory cells when pretreated ex vivo with IgM. B cells
Externí odkaz:
https://doaj.org/article/0c3818918fce4e6a85ea7f7fbcd2caf3
Autor:
Samir M. Parikh, Anupam Agarwal, Amandeep Bajwa, Sanjeev Kumar, Sherry G. Mansour, Mark D. Okusa, Jorge Cerda
Publikováno v:
Kidney360. 3:1445-1448
Autor:
Daphne H. Knicely, Mark D. Okusa
Publikováno v:
Nephrology Self-Assessment Program. 21:12-28
Autor:
Shinji Tanaka, Shuqiu Zheng, Yugesh Kharel, Russell G. Fritzemeier, Tao Huang, Daniel Foster, Nabin Poudel, Eibhlin Goggins, Yusuke Yamaoka, Kinga P. Rudnicka, Jonathan E. Lipsey, Hope V. Radel, Sophia M. Ryuh, Tsuyoshi Inoue, Junlan Yao, Diane L. Rosin, Susan R. Schwab, Webster L. Santos, Kevin R. Lynch, Mark D. Okusa
Publikováno v:
Science Translational Medicine. 14
Chronic kidney disease (CKD), characterized by sustained inflammation and progressive fibrosis, is highly prevalent and can eventually progress to end-stage kidney disease. However, current treatments to slow CKD progression are limited. Sphingosine